Marcus D Ruopp1, Tara C Collins, Brian W Whitcomb, Enrique F Schisterman. 1. Division of Epidemiology, Statistics and Prevention Research, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20852, USA.
Abstract
OBJECTIVE: To assess the conflicting evidence whether low-dose aspirin is beneficial in IVF and to evaluate the meta-analysis performed by Gelbaya et al. and reported in March 2007 in Human Reproduction Update, in which they found no effects of low-dose aspirin and recommended discontinuing its use in IVF. We present a reanalysis of the effects of low-dose aspirin in IVF and raise methodological questions regarding the analysis by Gelbaya et al. DESIGN: A meta-analysis of prospective randomized trials evaluating the effects of low-dose aspirin in IVF. PATIENT(S): Women undergoing IVF/intracytoplasmic sperm injection. INTERVENTION(S): Low-dose acetylsalicylic acid (aspirin). MAIN OUTCOME MEASURE(S): Pregnancy rates, implantation rates, miscarriage rates. RESULT(S): Ten randomized clinical trials were included in the analysis. Clinical pregnancy rate per ET was significant when low-dose aspirin was compared with no treatment (risk ratio 1.15, 95% confidence interval 1.03-1.27). Nonsignificant estimates comparing low-dose aspirin with no treatment were found for implantation and miscarriage rates. CONCLUSION(S): Our results suggest that aspirin may increase clinical pregnancy rates and that more data are needed to resolve the issue. At this point, there is no reason to change clinical management and discontinue the use of aspirin.
OBJECTIVE: To assess the conflicting evidence whether low-dose aspirin is beneficial in IVF and to evaluate the meta-analysis performed by Gelbaya et al. and reported in March 2007 in Human Reproduction Update, in which they found no effects of low-dose aspirin and recommended discontinuing its use in IVF. We present a reanalysis of the effects of low-dose aspirin in IVF and raise methodological questions regarding the analysis by Gelbaya et al. DESIGN: A meta-analysis of prospective randomized trials evaluating the effects of low-dose aspirin in IVF. PATIENT(S): Women undergoing IVF/intracytoplasmic sperm injection. INTERVENTION(S): Low-dose acetylsalicylic acid (aspirin). MAIN OUTCOME MEASURE(S): Pregnancy rates, implantation rates, miscarriage rates. RESULT(S): Ten randomized clinical trials were included in the analysis. Clinical pregnancy rate per ET was significant when low-dose aspirin was compared with no treatment (risk ratio 1.15, 95% confidence interval 1.03-1.27). Nonsignificant estimates comparing low-dose aspirin with no treatment were found for implantation and miscarriage rates. CONCLUSION(S): Our results suggest that aspirin may increase clinical pregnancy rates and that more data are needed to resolve the issue. At this point, there is no reason to change clinical management and discontinue the use of aspirin.
Authors: Eran Kozer; Adriana Moldovan Costei; Rada Boskovic; Irena Nulman; Shekoufeh Nikfar; Gideon Koren Journal: Birth Defects Res B Dev Reprod Toxicol Date: 2003-02
Authors: Ingrid Hung Lok; Shing-Kai Yip; Lai Ping Cheung; Peter Ho Yin Leung; Christopher John Haines Journal: Fertil Steril Date: 2004-03 Impact factor: 7.329
Authors: Lindsay D Levine; Tiffany L Holland; Keewan Kim; Lindsey A Sjaarda; Sunni L Mumford; Enrique F Schisterman Journal: Can J Physiol Pharmacol Date: 2018-12-18 Impact factor: 2.273
Authors: Enrique F Schisterman; Sunni L Mumford; Karen C Schliep; Lindsey A Sjaarda; Joseph B Stanford; Laurie L Lesher; Jean Wactawski-Wende; Anne M Lynch; Janet M Townsend; Neil J Perkins; Shvetha M Zarek; Michael Y Tsai; Zhen Chen; David Faraggi; Noya Galai; Robert M Silver Journal: J Clin Endocrinol Metab Date: 2015-02-24 Impact factor: 5.958
Authors: Lindsey A Sjaarda; Rose G Radin; Robert M Silver; Emily Mitchell; Sunni L Mumford; Brian Wilcox; Noya Galai; Neil J Perkins; Jean Wactawski-Wende; Joseph B Stanford; Enrique F Schisterman Journal: J Clin Endocrinol Metab Date: 2017-05-01 Impact factor: 5.958